Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020)
Kymera Therapeutics (KYMR) posted quarterly Preferred Stock Liabilities of $5.9 million for Q2 2020, down 79.82% quarter-over-quarter from $29.2 million in Q4 2019.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Preferred Stock Liabilities for 2 consecutive years, with $5.9 million the latest figure, recorded in Q2 2020.
- In Q2 2020, Preferred Stock Liabilities changed N/A year-over-year to $5.9 million; the TTM figure through Jun 2020 stood at $5.9 million (changed N/A YoY), while the FY2019 annual figure was $29.2 million, changed N/A from the prior year.
- Preferred Stock Liabilities eased to $5.9 million in Q2 2020 per KYMR's latest filing, from $29.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $29.2 million in Q4 2019 and bottomed at $5.9 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 101.18 Mn |
| Dec 31, 2019 | 59.92 Mn |
| Sep 30, 2019 | 38.74 Mn |